GCN1

Across TCGA pan-cancer cohorts, GCN1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated GCN1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher GCN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GCN1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

CHOL, MESO, and UCEC are the cancer types where GCN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.019	0.800	<.001	24	view →
MESO	DFS	Median	III,IV	0.088	0.421	<.001	24	view →
UCEC	DFS	Median	All	0.978	0.603	<.001	24	view →
KIRP	OS	Median	All	0.111	0.702	.001	12	view →
LIHC	DFS	Median	All	0.077	0.527	.002	9	view →
SCLC	DFS	Median	II,III,IV	0.698	0.298	.049	7	view →
BLCA	DFS	Median	IV	0.131	0.471	.005	6	view →
PRAD	DFS	Median	All	0.447	0.888	<.001	6	view →
SKCM	DFS	Median	IV	0.134	0.589	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

GCN1–CHOL (OS)

Open the CHOL breakdown →